PT  - JOURNAL ARTICLE
AU  - Fenton, Norman E
AU  - McLachlan, Scott
AU  - Lucas, Peter
AU  - Dube, Kudakwashe
AU  - Hitman, Graham A
AU  - Osman, Magda
AU  - Kyrimi, Evangelia
AU  - Neil, Martin
TI  - A Bayesian network model for personalised COVID19 risk assessment and contact tracing
AID  - 10.1101/2020.07.15.20154286
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.07.15.20154286
4099  - http://medrxiv.org/content/early/2021/01/05/2020.07.15.20154286.short
4100  - http://medrxiv.org/content/early/2021/01/05/2020.07.15.20154286.full
AB  - Concerns about the practicality and effectiveness of using Contact Tracing Apps (CTA) to reduce the spread of COVID19 have been well documented and, in the UK, led to the abandonment of the NHS CTA shortly after its release in May 2020. We present a causal probabilistic model (a Bayesian network) that provides the basis for a practical CTA solution that addresses some of the concerns and which has the advantage of minimal infringement of privacy. Users of the model can provide as much or little personal information as they wish about relevant risk factors, symptoms, and recent social interactions. The model then provides them feedback about the likelihood of the presence of asymptotic, mild or severe COVID19 (past, present and projected). When the model is embedded in a smartphone app, it can be used to detect new outbreaks in a monitored population and identify outbreak locations as early as possible. For this purpose, the only data needed to be centrally collected is the probability the user has COVID19 and the GPS location.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge support from the EPSRC under project EP/P009964/1: PAMBAYESIAN: Patient Managed decision-support using Bayesian Networks and The Alan Turing Institute under the EPSRC grant EP/N510129/1. We also acknowledge the support of Agena.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLinks are provided in the article to data and model http://www.eecs.qmul.ac.uk/~norman/Models/covid19_for_contact_tracing_paper.cmpx